Filter Results
:
(924)
Show Results For
-
All HBS Web
(924)
- People (2)
- News (63)
- Research (754)
- Events (1)
- Multimedia (2)
- Faculty Publications (647)
Show Results For
-
All HBS Web
(924)
- People (2)
- News (63)
- Research (754)
- Events (1)
- Multimedia (2)
- Faculty Publications (647)
- 02 Mar 2010
- First Look
First Look: March 2
innovation in a wide range of other industries, including pharmaceuticals and biotechnology, IT and telecommunications, defense, chemicals, and agriculture. We believe that there are valuable lessons in this research for the energy...
View Details
Keywords:
Martha Lagace
- February 2010 (Revised September 2011)
- Case
Roche's Acquisition of Genentech
By: Carliss Y. Baldwin, Bo Becker and Vincent Marie Dessain
Franz Humer, CEO of the Roche Group, must decide whether to mount a hostile tender offer for the publicly-owned shares of Roche's biotechnology subsidiary, Genentech. The case provides opportunities to analyze Roche's strategy with respect to Genentech, the pros and...
View Details
Keywords:
Mergers and Acquisitions;
Business Subsidiaries;
Negotiation Offer;
Organizational Culture;
Corporate Strategy;
Biotechnology Industry;
Biotechnology Industry;
Switzerland
Baldwin, Carliss Y., Bo Becker, and Vincent Marie Dessain. "Roche's Acquisition of Genentech." Harvard Business School Case 210-040, February 2010. (Revised September 2011.)
- July 2001 (Revised August 2005)
- Case
Medicines Company, The
It is early 2001 and the Medicines Co. just received FDA approval to market Angiomax, a blood thinner to be used during angioplasties and heart procedures. It is intended to be a better alternative to Heparin, an 80-year-old drug that costs less then $10 per dose. The...
View Details
Keywords:
Business Model;
Change Management;
Decision Choices and Conditions;
Cost Management;
Price;
Product Marketing;
Product Launch;
Product Development;
Risk and Uncertainty;
Health Industry;
Health Industry
Gourville, John T. "Medicines Company, The." Harvard Business School Case 502-006, July 2001. (Revised August 2005.)
- September 2010 (Revised July 2013)
- Case
Alnylam Pharmaceuticals: Building Value from the IP Estate
By: Willy C. Shih and Sen Chai
The learning objective of this case is to help students recognize the interplay between intellectual property (IP) rights and corporate strategy. We do this by examining what is a fairly atypical circumstance today in which a single firm is able to secure what it...
View Details
Keywords:
Patents;
Lawsuits and Litigation;
Rights;
Competitive Strategy;
Corporate Strategy;
Biotechnology Industry;
Biotechnology Industry;
United States
Shih, Willy C., and Sen Chai. "Alnylam Pharmaceuticals: Building Value from the IP Estate." Harvard Business School Case 611-009, September 2010. (Revised July 2013.)
- 03 Feb 2015
- First Look
First Look: February 3
field and other business fields complements the contributions from industrial organization economics (IO). These business fields also offer theoretical and empirical challenges to the IO paradigm, which dominates antitrust analysis. The...
View Details
Keywords:
Sean Silverthorne
- 15 Jan 2013
- First Look
First Look: January 15
circumscribe citizen-employees, and they engage in production and trade. But individual corporations are no longer adequate to serve as the primary unit of analysis. Over the years, systems of distributed innovation-so-called business ecosystems-have become...
View Details
Keywords:
Sean Silverthorne
- May 1998 (Revised May 1999)
- Case
Biopure Corp.
It is early 1998 and Biopure Corp., a small biopharmaceutical firm with no sales revenues in its ten-year history, has just received government approval to release Oxyglobin, a revolutionary new "blood substitute" designed to replace the need for donated animal blood...
View Details
Keywords:
Segmentation;
Marketing Strategy;
Engineering;
Budgets and Budgeting;
Sales;
Transformation;
Markets;
Debates;
Product Launch;
Pharmaceutical Industry
Gourville, John T. "Biopure Corp." Harvard Business School Case 598-150, May 1998. (Revised May 1999.)
- 15 Jun 2007
- Research & Ideas
Remembering Alfred Chandler
great-grandfather, the business editor and analyst Henry Varnum Poor, to 2 recent volumes, published while he was in his 80s: Inventing the Electronic Century: The Epic Story of the Consumer Electronics and Computer Industries and Shaping...
View Details
Keywords:
by Sean Silverthorne
- September 1990 (Revised November 1991)
- Case
Merck & Co., Inc. (B)
In late 1986, Merck revised its performance review and pay practices. The most important change was a shift from an absolute rating system to a forced-distribution system in which managers are forced to adhere to a given distribution of performance ratings. Other major...
View Details
Murphy, Kevin J. "Merck & Co., Inc. (B)." Harvard Business School Case 491-006, September 1990. (Revised November 1991.)
- 08 Apr 2009
- Research & Ideas
Clayton Christensen on Disrupting Health Care
interrelated. People who have studied this industry for a long time have come up with a number of feasible ideas to get at the cost problem, including high-deductible insurance and health savings accounts. But until we make sure that the...
View Details
- June 2004 (Revised June 2006)
- Supplement
Vertex Pharmaceuticals: R&D Portfolio Management (A)
By: Gary P. Pisano, Lee Fleming and Eli Strick
Vertex Pharmaceuticals, Inc., a drug discovery company that recently decided to pursue a vertically integrated business model, chose to build up its clinical development and commercial capabilities and infrastructure. For the first time in its history, Vertex will...
View Details
Pisano, Gary P., Lee Fleming, and Eli Strick. "Vertex Pharmaceuticals: R&D Portfolio Management (A)." Harvard Business School Supplement 604-101, June 2004. (Revised June 2006.)
- February 2024
- Case
Compass Pathways: Pioneering Psychedelic Treatment
By: Tiona Zuzul, Kisha Lashley and Gamze Yucaoglu
This case follows Compass Pathways, a pioneering company developing treatment for depression based on psilocybin, the compound found in ‘magic mushrooms.’ Psilocybin was a federally illegal substance in the U.S., and a “Schedule I” drug, defined as a drug “with no...
View Details
Keywords:
Commercialization;
Corporate Strategy;
Competitive Strategy;
Product Launch;
Health Testing and Trials;
Research and Development;
Laws and Statutes;
Pharmaceutical Industry;
Europe;
United States;
United Kingdom
Zuzul, Tiona, Kisha Lashley, and Gamze Yucaoglu. "Compass Pathways: Pioneering Psychedelic Treatment." Harvard Business School Case 724-412, February 2024.
- 08 Feb 2000
- Research & Ideas
Building Effective R&D Capabilities Abroad
to commercialize its R&D more effectively in foreign markets. Until then, Eli Lilly had operated one home-base-augmenting laboratory site abroad and some small sites in industrialized countries for clinical testing and drug approval...
View Details
Keywords:
by Walter Kuemmerle
- October 2000 (Revised March 2003)
- Case
Merck & Company: Evaluating a Drug Licensing Opportunity
By: Richard S. Ruback and David B Krieger
This explores the valuation of an opportunity to license a compound before it enters clinical trials. Describes Merck's decision tree evaluation process is presented. Information required to evaluate a specific licensing opportunity is provided, including the costs of...
View Details
Keywords:
Decision Making;
Cost vs Benefits;
Opportunities;
Valuation;
Outcome or Result;
Pharmaceutical Industry
Ruback, Richard S., and David B Krieger. "Merck & Company: Evaluating a Drug Licensing Opportunity." Harvard Business School Case 201-023, October 2000. (Revised March 2003.)
- Web
Strategy Awards & Honors - Faculty & Research
Economics at the International Industrial Organization Conference for "Rising Markups and the Role of Consumer Preferences" with Hendrik Döpper, Nathan H. Miller, and Joel Stiebale. Frank Nagle: Received a GitHub Research Grant in 2022....
View Details
- Web
2022 Reunion Presentations - Alumni
Senior Lecturer Kristin W. Mugford (MBA 1993) + More Info – Less Info Over the last decade, firms have begun to recognize the power of gender diversity and have worked to actively hire and retain more women. While we see improved diversity at junior levels, View Details
- November 2016
- Case
Transformation at Eli Lilly & Co. (A)
By: William R. Kerr and Alexis Brownell
Faced with the imminent loss of 40% of its revenues due to patent expirations, pharma giant Eli Lilly sets out on a dramatic transformation process in 2009. The case considers how Lilly restructured the organization into business areas to aid better decision-making,...
View Details
Keywords:
Eli Lilly;
Restructuring;
R&D;
Transformation;
Organizational Change and Adaptation;
Organizational Structure;
Pharmaceutical Industry;
Indianapolis
Kerr, William R., and Alexis Brownell. "Transformation at Eli Lilly & Co. (A)." Harvard Business School Case 817-070, November 2016.
- 15 Dec 2003
- Research & Ideas
The New Global Business Manager
now we see new competitors come from smaller countries that, because their home markets are too small to support them, are moving immediately onto the global stage. We also see whole industries that are being born global, particularly the...
View Details
Keywords:
by Cynthia Churchwell
- 01 Oct 2001
- News
Guy de Chazal: Changing Focus
venture capital with Citicorp. "The industry was much, much smaller in those days," he says. "A few hundred million dollars a year, versus almost a hundred billion today." Drawing on his experience with Morgan Stanley since 1986, he...
View Details
Keywords:
Deborah Blagg
- January 2017
- Case
The Six CEOs of Tyco International Ltd.
By: John R. Wells and Gabriel Ellsworth
In September 2016, Johnson Controls, Inc. completed the acquisition of Tyco International PLC, a $9.9 billion business with operating profits of $884 million. The purchase consideration was $14.4 billion. Although the deal was billed as a merger, Ireland-based Tyco...
View Details
Keywords:
Tyco;
Dennis Kozlowski;
Edward Breen;
Fire Safety;
Fire Protection;
Security;
Packaging;
Securities And Exchange Commission;
Fraud;
Accounting;
Accounting Audits;
Earnings Management;
Financial Statements;
Goodwill Accounting;
Acquisition;
Mergers and Acquisitions;
Business Conglomerates;
Business Divisions;
Business Exit or Shutdown;
Business Growth and Maturation;
Business Headquarters;
Business Model;
Business Organization;
For-Profit Firms;
Restructuring;
Crime and Corruption;
Engineering;
Applied Optics;
Chemicals;
Construction;
Metals and Minerals;
Ethics;
Finance;
Cash Flow;
Public Equity;
Stock Options;
Financing and Loans;
Initial Public Offering;
Profit;
Revenue;
Geographic Location;
Geographic Scope;
Global Range;
Globalized Firms and Management;
Multinational Firms and Management;
Corporate Accountability;
Corporate Disclosure;
Health Care and Treatment;
Business History;
Executive Compensation;
Selection and Staffing;
Courts and Trials;
Lawfulness;
Lawsuits and Litigation;
Business or Company Management;
Goals and Objectives;
Growth and Development Strategy;
Market Entry and Exit;
Public Ownership;
Problems and Challenges;
Strategy;
Business Strategy;
Competition;
Competitive Strategy;
Competitive Advantage;
Consolidation;
Corporate Strategy;
Diversification;
Expansion;
Horizontal Integration;
Value;
Chemical Industry;
Chemical Industry;
Chemical Industry;
Chemical Industry;
Chemical Industry;
Chemical Industry;
Chemical Industry;
Chemical Industry;
Chemical Industry;
Chemical Industry;
Chemical Industry;
Chemical Industry;
Chemical Industry;
Republic of Ireland;
Switzerland;
Bermuda;
United States;
New Hampshire
Wells, John R., and Gabriel Ellsworth. "The Six CEOs of Tyco International Ltd." Harvard Business School Case 717-459, January 2017.